Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic profile, safety, and
tolerability of a single intravenous (IV) dose of delafloxacin in normal healthy subjects and
subjects with mild, moderate, or severe hepatic impairment.